Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 73Neoplasms 46Squamous Cell Carcinoma of Head and Neck 45Head and Neck Neoplasms 35Lung Neoplasms 34Uterine Cervical Neoplasms 27Neoplasm Metastasis 26Unspecified Adult Solid Tumor, Protocol Specific 24Stomach Neoplasms 24Ovarian Neoplasms 24Small Cell Lung Carcinoma 21Pancreatic Neoplasms 19Colorectal Neoplasms 18Cholangiocarcinoma 17Carcinoma, Squamous Cell 17Esophageal Neoplasms 16Breast Neoplasms 15Mesothelioma, Malignant 14Melanoma 13Urinary Bladder Neoplasms 12Mesothelioma 11Fallopian Tube Neoplasms 11Carcinoma, Ovarian Epithelial 11Sarcoma 9Gallbladder Neoplasms 9Esophageal Squamous Cell Carcinoma 9Biliary Tract Neoplasms 9Carcinoma 8Triple Negative Breast Neoplasms 7Recurrence 7

Interventions

sintilimab 1fludarabine 1WW Domain-Containing Oxidoreductase 1Pemetrexed 1Interleukin-2 1Cyclophosphamide 1Cisplatin 1Cetuximab 1Carboplatin 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced Non-Small Cell Lung Cancer × Cisplatin × Clear all
NCT05504278 2025-01-27

Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Recruiting
144 enrolled
Thoracic

Advanced Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡